# A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

> **NCT03405454** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 46 (estimated)

## Conditions studied

- Ovarian Clear Cell Carcinoma

## Interventions

- **DRUG:** durvalumab
- **DRUG:** standard chemotherapy

## Key facts

- **NCT ID:** NCT03405454
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-09
- **Primary completion:** 2021-09-15
- **Final completion:** 2022-03-15
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2018-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03405454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03405454, "A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03405454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*